Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2563)

CORRIGENDUM ANNOUNCEMENT

Reference is made to the Announcement on the Resolution of the Board of Directors (the "**Announcement**") dated 16 July 2025. Unless otherwise stated, definitions and terms used herein shall bear the same meanings as defined in the Announcement.

This corrigendum announcement is published for the purpose of correcting (i) the pricing method for inventories under paragraph "(1) CHANGES IN PRICING METHOD OF INVENTORIES" on page 1 of the Announcement, clarifying the change applies to inventories rather than raw materials; and (ii) the financial reporting standards under paragraph "(2) ADOPTION OF THE CHINA ACCOUNTING STANDARDS FOR BUSINESS ENTERPRISES" on page 2 of the Announcement, clarifying that the Company has been preparing its financial statements under both CASBE and Hong Kong Financial Reporting Standards instead of IFRS. Such discrepancy was due to typo error and the amended parts were underlined.

(1) CHANGES IN PRICING METHOD OF INVENTORIES

In order to reflect the cost fluctuations of inventory more objectively and timely and better align with the current business operation model, enhance the accuracy and comparability of cost accounting, thereby facilitating the management decision-making, subject to the approval by the Directors, the pricing method for issue of inventories was amended from the original method of first-in-first-out to weighted average method with effect from 1 January 2025.

(2) ADOPTION OF THE CHINA ACCOUNTING STANDARDS FOR BUSINESS ENTERPRISES

The Company has been preparing its financial statements in accordance with both CASBE and HKFRS Accounting Standards since the date on which the H Shares became listed on the Stock Exchange.

Except as stated above, all other information contained in the Announcement remains unchanged.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 18 July 2025

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.